Clinical Trials
35 trialsCMML/AML
Kura Oncology, Inc.
Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations
Kura Oncology, Inc.
PTCL
Kura Oncology, Inc.
AIM-HN/SEQ-HN
Kura Oncology, Inc.
Combination Chemotherapy Plus Radiation Therapy With or Without Tipifarnib in Treating Patients With Locally Advanced Pancreatic Cancer
National Cancer Institute (NCI)
Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma
National Cancer Institute (NCI)
Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer
National Cancer Institute (NCI)
R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas
National Institutes of Health Clinical Center (CC)
S9924 R115777 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
SWOG Cancer Research Network
Tipifarnib in Treating Patients With Recurrent Bladder Cancer
University Health Network, Toronto
Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed, Previously Untreated Acute Myeloid Leukemia
National Cancer Institute (NCI)
Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
R115777 in Treating Patients With Advanced Bladder Cancer
National Cancer Institute (NCI)
Tipifarnib in Treating Young Patients With Recurrent or Progressive High-Grade Glioma, Medulloblastoma, Primitive Neuroectodermal Tumor, or Brain Stem Glioma
National Cancer Institute (NCI)
R115777 in Treating Patients With Progressive, Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Fox Chase Cancer Center
Tipifarnib Plus Tamoxifen in Treating Women With Metastatic Breast Cancer
National Cancer Institute (NCI)
Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast Cancer
National Cancer Institute (NCI)
Tipifarnib in Treating Patients With Metastatic Malignant Melanoma
National Cancer Institute (NCI)
Tipifarnib in Treating Patients With Myelofibrosis and Myeloid Metaplasia
National Cancer Institute (NCI)
Tipifarnib, Gemcitabine, and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Combination Chemotherapy Followed By Donor Bone Marrow or Umbilical Cord Blood Transplant in Treating Children With Newly Diagnosed Juvenile Myelomonocytic Leukemia
National Cancer Institute (NCI)
Tipifarnib and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
National Cancer Institute (NCI)
Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
National Cancer Institute (NCI)
Capecitabine and Tipifarnib in Treating Women With Taxane-Resistant Metastatic Breast Cancer
National Cancer Institute (NCI)
R115777 in Treating Patients Who Have Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
Study of Letrozole Plus Tipifarnib or Placebo in the Treatment of Advanced Breast Cancer
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
S0432 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
R115777 in Treating Patients With Relapsed Small Cell Lung Cancer
NYU Langone Health
Phase II Evaluation of FTase Inhibitor (FTI)in Treatment of Advanced Multiple Myeloma
H. Lee Moffitt Cancer Center and Research Institute
S9923 R115777 in Treating Patients With Advanced Colorectal Cancer
SWOG Cancer Research Network
Phase II Trial to Assess the Radiosensitizing Effect of ZARNESTRA in Patients With Glioblastoma Multiforme
Institut Claudius Regaud
R115777 in Treating Patients With Recurrent or Metastatic Non-small Cell Lung Cancer
Mayo Clinic
A Phase 2 Study of Farnesyl Transferase Inhibitor (R115777, Tipifarnib) in Patients With Refractory or Relapsed Acute Myeloid Leukemia.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Study of Tipifarnib as Postconsolidation Therapy for Acute Myeloid Leukemia in Patients 60 Years and Older
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.